Contineum Therapeutics Statistics
Total Valuation
CTNM has a market cap or net worth of $530.51 million. The enterprise value is $291.14 million.
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, after market close.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CTNM has 37.39 million shares outstanding. The number of shares has increased by 21.17% in one year.
| Current Share Class | 32.72M |
| Shares Outstanding | 37.39M |
| Shares Change (YoY) | +21.17% |
| Shares Change (QoQ) | +20.98% |
| Owned by Insiders (%) | 0.82% |
| Owned by Institutions (%) | 68.95% |
| Float | 27.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 77.07 |
| PB Ratio | 2.12 |
| P/TBV Ratio | 2.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 38.00, with a Debt / Equity ratio of 0.03.
| Current Ratio | 38.00 |
| Quick Ratio | 37.00 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.88% and return on invested capital (ROIC) is -786.04%.
| Return on Equity (ROE) | -26.88% |
| Return on Assets (ROA) | -18.18% |
| Return on Invested Capital (ROIC) | -786.04% |
| Return on Capital Employed (ROCE) | -26.25% |
| Weighted Average Cost of Capital (WACC) | 9.03% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 51 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +209.15% in the last 52 weeks. The beta is 0.89, so CTNM's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +209.15% |
| 50-Day Moving Average | 13.02 |
| 200-Day Moving Average | 12.53 |
| Relative Strength Index (RSI) | 63.78 |
| Average Volume (20 Days) | 431,534 |
Short Selling Information
The latest short interest is 1.65 million, so 4.43% of the outstanding shares have been sold short.
| Short Interest | 1.65M |
| Short Previous Month | 1.43M |
| Short % of Shares Out | 4.43% |
| Short % of Float | 6.00% |
| Short Ratio (days to cover) | 8.65 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -66.85M |
| Pretax Income | -58.44M |
| Net Income | -58.44M |
| EBITDA | -66.53M |
| EBIT | -66.85M |
| Earnings Per Share (EPS) | -$1.91 |
Full Income StatementBalance Sheet
The company has $246.33 million in cash and $6.95 million in debt, giving a net cash position of $239.37 million or $6.40 per share.
| Cash & Cash Equivalents | 246.33M |
| Total Debt | 6.95M |
| Net Cash | 239.37M |
| Net Cash Per Share | $6.40 |
| Equity (Book Value) | 250.04M |
| Book Value Per Share | 6.69 |
| Working Capital | 246.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$57.17 million and capital expenditures -$496,000, giving a free cash flow of -$57.66 million.
| Operating Cash Flow | -57.17M |
| Capital Expenditures | -496,000 |
| Depreciation & Amortization | 328,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -57.66M |
| FCF Per Share | -$1.54 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |